Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer

被引：30

作者：

Zhang, Wen-Ji ^{[1
,2
]}

Li, Yong ^{[3
]}

Wei, Meng-Ning ^{[1
,2
]}

Chen, Yao ^{[1
,2
]}

Qiu, Jian-Ge ^{[1
,2
]}

Jiang, Qi-Wei ^{[1
,2
]}

Yang, Yang ^{[1
,2
]}

Zheng, Di-Wei ^{[1
,2
]}

Qin, Wu-Ming ^{[1
,2
]}

Huang, Jia-Rong ^{[1
,2
]}

Wang, Kun ^{[1
,2
]}

Zhang, Wen-Juan ^{[4
]}

Wang, Yi-Jun ^{[5
]}

Yang, Dong-Hua ^{[5
]}

Chen, Zhe-Sheng ^{[5
,6
]}

Shi, Zhi ^{[1
,2
]}

机构：

[1] Jinan Univ, Dept Cell Biol, Guangzhou 510632, Guangdong, Peoples R China

[2] Jinan Univ, Inst Biomed, Natl Engn Res Ctr Genet Med, Guangdong Prov Key Lab Bioengn Med,Coll Life Sci, Guangzhou 510632, Guangdong, Peoples R China

[3] Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Gastrointestinal Surg & Gen Surg, Guangzhou 510080, Guangdong, Peoples R China

[4] Jinan Univ, Dept Prevent Med, Coll Med, Guangzhou 510632, Guangdong, Peoples R China

[5] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY 11439 USA

[6] Jinan Univ, Coll Pharm, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Guangdong, Peoples R China

来源：

CANCER LETTERS | 2017年 / 386卷

基金：

中国国家自然科学基金;

关键词：

Regorafenib; Lapatinib; Targeted therapy; Combination chemotherapy; Colorectal cancer; MULTIDRUG-RESISTANCE; BREAST-CANCER; DRUG-SENSITIVITY; PHASE-3; TRIAL; TUMOR-GROWTH; COLON-CANCER; INHIBITOR; CELLS; COMBINATION; MULTICENTER;

D O I：

10.1016/j.canlet.2016.11.011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Regorafenib significantly prolongs overall survival in patients with metastatic colorectal cancer (mCRC), but the overall clinical efficacy of regorafenib remains quite limited. Combination chemotherapy is a potentially promising approach to enhance anticancer activity, overcome drug resistance, and improve disease-free and overall survival. The current study investigates the antitumor activity of regorafenib in combination with lapatinib in preclinical models of human CRC. Our results show improved antitumor efficacy when regorafenib is combined with lapatinib both in vitro and in vivo. Furthermore, pharmacokinetic analyses revealed that regorafenib and lapatinib do not influence on each plasma concentration. The finding that regorafenib in combination with lapatinib have synergistic activity warrants further clinical investigation of this beneficial combination as a potential treatment strategy for CRC patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

引用

页码：100 / 109

页数：10

共 50 条

[1] Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
Yuan, Tao
Wu, Ruilin
Wang, Weihua
Liu, Yue
Kong, Wencheng
Yang, Bo
He, Qiaojun
Zhu, Hong
FRONTIERS IN PHARMACOLOGY, 2023, 14
[2] Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Schmieder, Roberta
Hoffmann, Jens
Becker, Michael
Bhargava, Ajay
Mueller, Tina
Kahmann, Nicole
Ellinghaus, Peter
Adams, Robert
Rosenthal, Andre
Thierauch, Karl-Heinz
Scholz, Arne
Wilhelm, Scott M.
Zopf, Dieter
INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (06) : 1487 - 1496
[3] Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
Daudigeos-Dubus, Estelle
Le Dret, Ludivine
Lanvers-Kaminsky, Claudia
Bawa, Olivia
Opolon, Paule
Vievard, Albane
Villa, Irene
Pages, Melanie
Bosq, Jacques
Vassal, Gilles
Zopf, Dieter
Geoerger, Birgit
PLOS ONE, 2015, 10 (11):
[4] The preclinical development of regorafenib for the treatment of colorectal cancer
Miura, Koh
Satoh, Masayuki
Kinouchi, Makoto
Yamamoto, Kuniharu
Hasegawa, Yasuhiro
Philchenkov, Alex
Kakugawa, Yoichiro
Fujiya, Tsuneaki
EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (09) : 1087 - 1101
[5] Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
Kissel, Maria
Berndt, Sandra
Fiebig, Lukas
Kling, Simon
Ji, Qunsheng
Gu, Qingyang
Lang, Tina
Hafner, Frank-Thorsten
Teufel, Michael
Zopf, Dieter
ONCOTARGET, 2017, 8 (63): : 107096 - 107108
[6] Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Yang, Hong
Higgins, Brian
Kolinsky, Kenneth
Packman, Kathryn
Bradley, William D.
Lee, Richard J.
Schostack, Kathleen
Simcox, Mary Ellen
Kopetz, Scott
Heimbrook, David
Lestini, Brian
Bollag, Gideon
Su, Fei
CANCER RESEARCH, 2012, 72 (03) : 779 - 789
[7] Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer
Pitts, Todd M.
Bradshaw-Pierce, Erica L.
Bagby, Stacey M.
Hyatt, Stephanie L.
Selby, Heather M.
Spreafico, Anna
Tentler, John J.
McPhillips, Kelly
Klauck, Peter J.
Capasso, Anna
Diamond, Jennifer R.
Davis, S. Lindsey
Tan, Aik Choon
Arcaroli, John J.
Purkey, Alicia
Messersmith, Wells A.
Ecsedy, Jeffery A.
Eckhardt, S. Gail
ONCOTARGET, 2016, 7 (31) : 50290 - 50301
[8] Luteolin enhances the antitumor activity of lapatinib in human breast cancer cells
Zhang, Lingyan
Yang, Fan
Huang, Li
Liu, Aixue
Zhang, Jiren
BIOMEDICAL RESEARCH-INDIA, 2017, 28 (11): : 4902 - 4907
[9] Regorafenib antitumor activity alone and in combination with radio or chemotherapy in preclinical models of pediatric solid tumors.
Daudigeos-Dubus, Estelle
Le Dret, Ludivine
Lanvers-Kaminsky, Claudia
Bawa, Olivia
Opolon, Paule
Villa, Irene
Bosq, Jacques
Vassal, Gilles
Zopf, Dieter
Geoerger, Birgit
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[10] Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Zopf, Dieter
Fichtner, Iduna
Bhargava, Ajay
Steinke, Wolfram
Thierauch, Karl-Heinz
Diefenbach, Konstanze
Wilhelm, Scott
Hafner, Frank-Thorsten
Gerisch, Michael
CANCER MEDICINE, 2016, 5 (11): : 3176 - 3185

← 1 2 3 4 5 →